Announcements Trials
Browse Landscape

Phase

Phase 2 74Phase 3 46Phase 1 19Phase 1/2 14Phase NA 11Phase 4 7Phase 2/3 5Phase EARLY_PHASE1 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5CNS 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3NSCLC 2Brain Neoplasms 2Respiratory Tract Diseases 1Neoplasms 1Lung Neoplasms 1

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Gefitinib × Thoracic × Clear all
NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT02326285 2018-01-23

NeoIntercal

AIO-Studien-gGmbH

Phase 2/3 Terminated
1 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00259064 2016-06-02

INSTEP

AstraZeneca

Phase 2/3 Completed
216 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

NCT02338011 2015-01-26

EGFR

Shanghai Chest Hospital

Phase 2/3 Unknown
210 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡